ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2016
Utilisation of the ESMO-MCBS in practice of HTA.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2018Pooled it
- The ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) visualisation: picturing the evidence of clinical benefit of clinical trial data.ESMO real world data and digital oncology · 2025Article
- Value-Based Healthcare in Practice: IDEATE, a Collaboration to Design and Test an Outcomes-Based Agreement for a Medicine in Wales.PharmacoEconomics · 2025Article
- Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.JAMA oncology · 2024Article
- A Comparison of Additional Benefit Assessment Methods for Time-to-Event Endpoints Using Hazard Ratio Point Estimates or Confidence Interval Limits by Means of a Simulation Study.Medical decision making : an international journal of the Society for Medical Decision Making · 2024Article
- Analysis of oncological drugs authorised in Spain in the last decade: association between clinical benefit and reimbursement.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Article
- First-line tremelimumab plus durvalumab and chemotherapyFrontiers in pharmacology · 2023Article
- Introduction of managed entry agreements in Korea: Problem, policy, and politics.Frontiers in pharmacology · 2023Article
- Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers.Frontiers in pharmacology · 2022Article
- Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries.Frontiers in pharmacology · 2022Article
- Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology.International journal of environmental research and public health · 2021Article
- Integrative Review of Managed Entry Agreements: Chances and Limitations.PharmacoEconomics · 2020Review
- Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished-What is Next?HemaSphere · 2020Article
- EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies.ESMO open · 2020Article
- Development of the First Value Assessment Index System for Off-Label Use of Antineoplastic Agents in China: A Delphi Study.Frontiers in pharmacology · 2020Article
- Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions.Frontiers in pharmacology · 2020Article
- Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems.Breast care (Basel, Switzerland) · 2019Review
- Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.Frontiers in public health · 2018Review
- Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.Frontiers in pharmacology · 2017Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27502718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.